Form 4: Wave Life Sciences Director Receives Equity Grant

Wave Life Sciences director Ken Takanashi was granted 12,700 restricted share units and options for 76,200 ordinary shares as part of the company's 2025 Non-Employee Director Compensation Policy.

Summary

• Director Ken Takanashi of Wave Life Sciences Ltd. was granted 12,700 Restricted Share Units (RSUs) and options to purchase 76,200 ordinary shares.
• These equity awards were granted on August 11, 2025, under the company's 2025 Non-Employee Director Compensation Policy.
• The RSUs were granted at a price of $0.00 per share, while the options have an exercise price of $8.105 per share.
• Both the RSUs and the options are scheduled to vest 100% on the earlier of the company's 2026 annual general meeting or August 11, 2026.
• Following these transactions, Ken Takanashi directly beneficially owns 5,729,003 ordinary shares and 76,200 share options.

Sentiment

Score: 7

Explanation: The filing details a standard compensation grant to a director, which is a routine corporate governance event. It aligns the director's interests with shareholders, generally viewed as a positive or neutral development.

Positives

• The grant of equity awards to Director Ken Takanashi aligns his financial interests with those of the company's shareholders.
• The compensation policy for non-employee directors helps attract and retain qualified board members, contributing to stable corporate governance.

Future Outlook

NA

Management Comments

• The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy.
• The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy.

Industry Context

NA

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of the director's interests with shareholder value through equity ownership.

Next Steps

• Vesting of 12,700 Restricted Share Units on the earlier of the 2026 annual general meeting or August 11, 2026.
• Vesting of options for 76,200 ordinary shares on the earlier of the 2026 annual general meeting or August 11, 2026.

Key Dates

Keywords

Wave Life Sciences, WVE, SEC Form 4, Insider Transaction, Equity Grant, Restricted Share Units, Stock Options, Director Compensation, Biotechnology, Pharmaceuticals